Literature DB >> 10951406

Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent.

I Itonaga1, Y Fujikawa, A Sabokbar, D W Murray, N A Athanasou.   

Abstract

Osteoprotegerin ligand (OPGL) is a newly discovered molecule which is essential for osteoclast differentiation. Both OPGL and its soluble decoy receptor, osteoprotegerin (OPG), which inhibits osteoclast formation, are known to be produced by osteoblasts and inflammatory cells found in the rheumatoid arthritis (RA) synovium. In this study, RA synovial macrophages were incubated in the presence or absence of OPGL, macrophage-colony stimulating factor (M-CSF), and dexamethasone for various time points. The results indicated that osteoclast formation from RA synovial macrophages is OPGL-dependent and that OPGL and M-CSF are the only humoral factors required for RA synovial macrophage-osteoclast differentiation. OPG was found to inhibit osteoclast formation by RA synovial macrophages in a dose-dependent manner. This study has shown that macrophages isolated from the synovium of RA patients are capable of differentiating into osteoclastic bone-resorbing cells; this process is OPGL- and M-CSF-dependent and is modulated by corticosteroids. Cellular (T and B cells, dendritic cells) and humoral factors in RA synovium and bone may influence osteoclast formation and bone resorption by controlling OPGL/OPG production. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951406     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH672>3.0.CO;2-W

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Authors:  Nathalie Saidenberg-Kermanac'h; Natacha Bessis; Delphine Lemeiter; Marie-Christine de Vernejoul; Marie-Christophe Boissier; Martine Cohen-Solal
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

2.  sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis.

Authors:  Gert E Hein; Marit Meister; Peter Oelzner; Sybille Franke
Journal:  Rheumatol Int       Date:  2008-01-03       Impact factor: 2.631

3.  Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.

Authors:  Jerome T Higgs; John S Jarboe; Joo Hyoung Lee; Diptiman Chanda; Carnellia M Lee; Champion Deivanayagam; Selvarangan Ponnazhagan
Journal:  Mol Cancer Res       Date:  2015-01-30       Impact factor: 5.852

4.  Stimulation of osteoclast formation by inflammatory synovial fluid.

Authors:  Iannis E Adamopoulos; Lynett Danks; Ichiro Itonaga; Rachel M Locklin; Afsie Sabokbar; David J P Ferguson; Nicholas A Athanasou
Journal:  Virchows Arch       Date:  2006-04-21       Impact factor: 4.064

5.  Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.

Authors:  M Skoumal; G Kolarz; G Haberhauer; W Woloszczuk; G Hawa; A Klingler
Journal:  Rheumatol Int       Date:  2005-05-12       Impact factor: 2.631

6.  Osteoclasts are essential for TNF-alpha-mediated joint destruction.

Authors:  Kurt Redlich; Silvia Hayer; Romeo Ricci; Jean-Pierre David; Makiyeh Tohidast-Akrad; George Kollias; Günter Steiner; Josef S Smolen; Erwin F Wagner; Georg Schett
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

7.  Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.

Authors:  T N Crotti; M D Smith; H Weedon; M J Ahern; D M Findlay; M Kraan; P P Tak; D R Haynes
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 8.  Bone destruction in arthritis.

Authors:  E M Gravallese
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

9.  Synovial macrophage-osteoclast differentiation in inflammatory arthritis.

Authors:  L Danks; A Sabokbar; R Gundle; N A Athanasou
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

10.  Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis.

Authors:  Shufeng Li; Wensheng Liao; Meng Chen; Shiying Shan; Yuanlin Song; Shuzhen Zhang; Haihan Song; Zhen Yuan
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.